Himalaya Nutravedics FY26 profit after tax rose 231.1% to Rs 739.0 lakh, according to the company's investor presentation filed with BSE on October 3, 2026. Himalaya Nutravedics India Ltd reported revenue from operations of Rs 4,306.8 lakh, up 105.1% from Rs 2,099.7 lakh in FY25.

EBITDA increased 171.0% to Rs 810.3 lakh from Rs 299.0 lakh. The EBITDA margin reached 18.8%, compared with 14.2% a year earlier, while the PAT margin expanded to 17.2% from 10.6%. FY25 profit after tax stood at Rs 223.2 lakh.

The presentation also showed a wider operating cash deficit alongside higher earnings. Cash outflow from operations increased to Rs 383.4 lakh, against Rs 139.1 lakh in FY25. Debtor days declined by eight days to 90 days.

Own brands account for over half of revenue

The company's own-brand revenue share increased to 51.1% in FY26 from 19.7% in FY25. Third-party manufacturing contributed the remaining 48.9%, compared with 80.4% a year earlier. Ayurvedic products represented 94.6% of FY26 revenue, with nutraceutical products accounting for 5.4%.

Kerala contributed 49.3% of revenue, down from 68.9% in FY25, as the share from other markets increased. Gujarat accounted for 13.2% and Uttar Pradesh for 11.7% of FY26 revenue. The company described its distribution footprint as 16 states and one Union Territory.

At its Cherlapally facility in Hyderabad, medicated oil capacity utilisation reached 90.2%, while softgel capsule utilisation stood at 63.7%. These figures are based on a single eight-hour shift per day; the presentation says the plant can operate up to three shifts daily.

Digital channels and portfolio expansion planned

Himalaya Nutravedics outlined plans to expand beyond its practitioner-driven distribution model while retaining its existing B2B network. Its proposed initiatives include:

  • A proprietary direct-to-consumer platform and expansion across e-commerce and quick-commerce marketplaces.
  • Rs 750 lakh from net proceeds proposed for branding, performance marketing and customer acquisition campaigns.
  • Additional own-brand products across pain management, gut health, women's wellness and neurological support.
  • Wider distribution in tier-2 and tier-3 markets, alongside stronger export compliance and product registration capabilities.

Incorporated in June 2022, the company began commercial manufacturing in September 2022 and operates both own-brand and third-party contract manufacturing businesses.